Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) saw a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 64,700 shares, a decrease of 28.0% from the February 28th total of 89,800 shares. Based on an average daily volume of 87,000 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.1% of the shares of the stock are sold short.
Xtant Medical Stock Performance
Shares of XTNT traded up $0.00 during trading hours on Thursday, hitting $0.47. 6,937 shares of the stock were exchanged, compared to its average volume of 74,922. The stock has a 50-day moving average price of $0.53. Xtant Medical has a 12-month low of $0.33 and a 12-month high of $1.03. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.88 and a current ratio of 2.12. The firm has a market capitalization of $65.35 million, a P/E ratio of -3.62 and a beta of 0.35.
Hedge Funds Weigh In On Xtant Medical
A hedge fund recently raised its stake in Xtant Medical stock. Geode Capital Management LLC lifted its stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 70.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 515,006 shares of the medical device company's stock after acquiring an additional 212,394 shares during the quarter. Geode Capital Management LLC owned 0.37% of Xtant Medical worth $348,000 at the end of the most recent reporting period. 69.33% of the stock is owned by hedge funds and other institutional investors.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
See Also
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
